Eligible patients were adults (≥18 years) with confirmed multiple myeloma based on IMWG diagnostic criteria and measurable disease at screening (serum M-protein ≥ 1 g/dL, or urine M-protein ≥ 200 mg/24 h, or abnormal free-light-chain ratio ≥ 10 mg/dL). This evidence concerns the gene MYOM2 and plasma cell myeloma.